Navigation Links
ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
Date:8/29/2007

SAN DIEGO, Aug. 29 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases, announced today that Evan M. Levine, ADVENTRX's chief executive officer, is scheduled to present at the 2007 Thomas Weisel Partners Healthcare Conference on Wednesday, September 5th, 2007 at 1:30 p.m. Eastern Daylight Time. The conference takes place in Boston at the Four Seasons Hotel, September 5 - 7, 2007.

The presentation will be webcast live via the "Investors" section of the Company's web site at http://www.adventrx.com under "Events." The webcast will be available for replay for 14 days and can be accessed through the same link.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases. The Company seeks to improve the performance and safety of existing treatments by addressing significant problems such as drug metabolism, bioavailability, excessive toxicity and treatment resistance. More information can be found on the Company's web site at http://www.adventrx.com.

Forward Looking Statements

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that ADVENTRX will be unable to raise sufficient capital to fund the projects necessary to meet its anticipated or stated goals and milestones; the ability to timely enroll subjects in and the results of ADVENTRX's current and anticipated clinical trials; the potential for ADVENTRX's product candidates to receive regulatory approval for one or more indications on a timely basis or at all, and the uncertain process of seeking regulatory approval; the market potential for ADVENTRX's product candidates and ADVENTRX's ability to compete in those markets; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at http://www.sec.gov.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to update any forward-looking statement, including as set forth in this press release, to reflect events or circumstances arising after the date on which it was made.


'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
4. Wisconsin firms to present at Cleantech venture capital event
5. New Sonic Foundry search engine finds words, phrases in video presentations
6. Lone Wisconsin firm to present at InvestMidwest
7. Sonic Foundry creates search engine for 7,000 expert video presentations
8. InvestMidWest calls for business presentations
9. Wicab to present BrainPort at Boston conference
10. Three more Wisconsin firms to present at venture forum
11. Six Wisconsin firms to present at BIO Mid-America VentureForum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... 2017 , ... Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, ... Health (NIMH) for the further advancement of the company’s 3-month olanzapine product ( DLP-119 ... to deliver therapeutic levels of olanzapine for a period of 3 months., “We are ...
(Date:2/24/2017)... , Feb. 24, 2017 Provectus ... or the "Company"), a clinical-stage oncology and dermatology ... the deadline to participate in its previously announced ... consisting of shares of common stock and Series ... holders of listed warrants. As ...
(Date:2/24/2017)... Feb. 24, 2017 Symic Bio, a biopharmaceutical ... new category of therapeutics, announced today the completion of ... peripheral artery disease. The trial will evaluate the safety ... in the reduction of restenosis following angioplasty. ... milestone for SB-030," said Nathan Bachtell , M.D., ...
(Date:2/24/2017)... KONG, Feb. 24, 2017 China Cord Blood Corporation ... China,s leading provider of cord blood collection, laboratory testing, ... today announced its unaudited financial results for the third ... ended December 31, 2016. Third Quarter of ... third quarter of fiscal 2017 increased by 18.6% to ...
Breaking Biology Technology:
(Date:2/3/2017)... 2017 A new independent identity strategy consultancy ... (IdSP) . Designed to fill a critical niche in ... founding partners Mark Crego and Janice ... in identity expertise that span federal governments, the 9/11 ... Crego-Kephart combined expertise has a common theme born from ...
(Date:2/2/2017)... Feb. 1, 2017  Central to its deep ... advances worldwide, The Japan Prize Foundation today announced ... have pushed the envelope in their respective fields ... Three scientists are being recognized with the 2017 ... not only contribute to the advancement of science ...
(Date:1/30/2017)... , Jan. 30, 2017   Invitae Corporation ... growing genetic information companies, today announced that it will ... and provide 2017 guidance on Monday, February 13, 2017, ... that day at 4:45 p.m. Eastern / 1:45 p.m. ... team will briefly review financial results, guidance, and recent ...
Breaking Biology News(10 mins):